Vernalis’ cough cold product, CCP-07, has successfully completed a single-dose comparative bioavailability study and will now progress into a multiple-dose study. A potential FDA filing remains on track for 2016. We retain a Buy recommendation.
21 Dec 2015
CCP-07 FDA filing remains on track for 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CCP-07 FDA filing remains on track for 2016
Vernalis’ cough cold product, CCP-07, has successfully completed a single-dose comparative bioavailability study and will now progress into a multiple-dose study. A potential FDA filing remains on track for 2016. We retain a Buy recommendation.